Future research in ITP: an ICIS consensus.

Authors:
John W Semple
John W Semple
Lund University
Professor of Transfusion Medicine
Lund, Skane | Sweden

Ann Hematol 2010 Jul 23;89 Suppl 1:19-23. Epub 2010 Mar 23.

Department of Pathology, Stanford University School of Medicine, L235, Stanford, CA, 94305, USA,

While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and optimize use of existing therapies. The answers to these questions are likely to impact our understanding of the pathogenesis and therapeutic targets of autoimmune disease in general.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-010-0917-1DOI Listing
July 2010
31 Reads
2.634 Impact Factor

Publication Analysis

Top Keywords

therapeutic targets
8
targets approaches
4
approaches clinical
4
clinical trials
4
trials rationalize
4
novel therapeutic
4
regard pathogenesis
4
pathogenesis disease
4
disease progression
4
identification novel
4
rationalize optimize
4
optimize existing
4
pathogenesis therapeutic
4
targets autoimmune
4
autoimmune disease
4
disease general
4
understanding pathogenesis
4
impact understanding
4
existing therapies
4
therapies answers
4

References

(Supplied by CrossRef)

F Rodeghiero et al.
Blood 2009

PE Abrahamson et al.
Eur J Haematol 2009

DB Cines et al.
Blood 2009

H Sukati et al.
Blood 2007

XL Zhang et al.
Blood 2009

ZX Guo et al.
Eur J Haematol 2009

B Olsson et al.
Blood 2008

B Olsson et al.
Nat Med 2003

W Zhang et al.
Blood 2009

Similar Publications